Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
1.075
+0.045 (4.35%)
Apr 17, 2025, 3:56 PM EDT - Market open
Silo Pharma Revenue
In the year 2024, Silo Pharma had annual revenue of $72.10K. Silo Pharma had revenue of $18.03K in the quarter ending December 31, 2024.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
54.86
Revenue / Employee
$24,034
Employees
3
Market Cap
4.82M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SILO News
- 23 days ago - Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - GlobeNewsWire
- 7 weeks ago - Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment - GlobeNewsWire
- 2 months ago - Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - GlobeNewsWire
- 2 months ago - Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia - GlobeNewsWire
- 3 months ago - Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment - GlobeNewsWire
- 3 months ago - Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain - GlobeNewsWire
- 4 months ago - Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia - GlobeNewsWire
- 5 months ago - Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management - GlobeNewsWire